PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics

Pharmacogenet Genomics. 2019 Jun;29(4):91-97. doi: 10.1097/FPC.0000000000000369.

Authors

Rachel Huddart¹, Russ B Altman^{1

2

3

4}, Teri E Klein^{1

4}

Affiliations

¹ Departments of Biomedical Data Sciences.
² Biomedical Engineering.
³ Genetics.
⁴ Medicine, Stanford University, Stanford, California, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Cytochrome P-450 CYP1A2 / genetics
Cytochrome P-450 CYP2D6 / genetics*
Cytochrome P-450 CYP2D6 / metabolism
Humans
Inactivation, Metabolic / genetics
Metabolic Networks and Pathways / drug effects*
Ondansetron / metabolism
Ondansetron / pharmacokinetics*
Ondansetron / therapeutic use
Receptors, Serotonin, 5-HT3 / genetics
Receptors, Serotonin, 5-HT3 / metabolism
Serotonin / metabolism
Serotonin Antagonists / metabolism
Serotonin Antagonists / pharmacokinetics
Serotonin Antagonists / therapeutic use
Tropisetron / metabolism
Tropisetron / pharmacokinetics*
Tropisetron / therapeutic use

Substances

Receptors, Serotonin, 5-HT3
Serotonin Antagonists
Serotonin
Ondansetron
Tropisetron
Cytochrome P-450 CYP1A2
Cytochrome P-450 CYP2D6

Grant support